Literature DB >> 15192124

HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.

Fumihiro Hommura1, Motoo Katabami, Virna D Leaner, Howard Donninger, Takita F Sumter, Linda M S Resar, Michael J Birrer.   

Abstract

The transcription complex activator protein-1 (AP-1) plays a role in a diverse number of cellular processes including proliferation, differentiation, and apoptosis. To identify AP-1-responsive target genes, we used a doxycycline-inducible c-Jun system in Rat1a cells. The HMG-I/Y chromatin binding protein was found to be up-regulated by c-Jun. Following induction of c-Jun expression, Rat1a cells under nonadherent growth conditions have sustained HMG-I/Y mRNA expression and 2-fold higher protein than uninduced cells. HMG-I/Y promoter reporter assays show that HMG-I/Y promoter activity increases in the presence of c-Jun expression, and gel mobility shift assays demonstrate that induced c-Jun binds to an AP-1 consensus site at position -1,091 in the HMG-I/Y promoter. Suppression of HMG-I/Y expression by its antisense sequence significantly reduces the ability of c-Jun-overexpressing Rat1a cells to grow in an anchorage-independent fashion. HMG-I/Y transforms Rat1a cells (although the colonies are smaller than that observed for the cells overexpressing c-Jun). Taken together, these results suggest that HMG-I/Y is a direct transcriptional target of c-Jun necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192124

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  23 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

2.  Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Stanley W Ashley; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

Review 3.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

Review 4.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

5.  Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Authors:  Dwella M Nelson; Biju Joseph; Joelle Hillion; Jodi Segal; Judith E Karp; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2011-07-05

6.  Hitting the bull's eye: targeting HMGA1 in cancer stem cells.

Authors:  Breann L Yanagisawa; Linda M S Resar
Journal:  Expert Rev Anticancer Ther       Date:  2014-01       Impact factor: 4.512

Review 7.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

8.  BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer.

Authors:  Ali Naderi; Ji Liu; Luke Hughes-Davies
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

9.  The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer.

Authors:  Bethany M Bush; Ashton T Brock; Jiayue A Deng; Ronald A Nelson; Takita Felder Sumter
Journal:  Cell Biochem Funct       Date:  2012-09-07       Impact factor: 3.685

10.  Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.

Authors:  J Kikuchi; I Kinoshita; Y Shimizu; S Oizumi; M Nishimura; M J Birrer; H Dosaka-Akita
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.